Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01634620 · ClinicalTrials.gov registry record

Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease

A clinical trial, sponsored by Aerocrine AB.

Completed
Registry status
200
Enrollment target

NCT01634620: Completed study, sponsored by Aerocrine AB.

NCT01634620 is a clinical trial that has completed, run by Aerocrine AB. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01634620 has completed, sponsored by Aerocrine AB.

COMPLETED
Registry status
200 participants
Enrollment target

Study Summary

Objective: To characterize FeNO levels that may be indicative of eosinophilic airway inflammation in patients with chronic obstructive airways disease Number of participants: Approximately 200 subjects will be enrolled Reference product: NIOX MINO® Instrument (09-1100) Performance assessments: Fractional Exhaled Nitric Oxide (FeNO) Measurements will be performed according to the "Perform FeNO Measurement" guidelines on page 7 of the NIOX MINO® User Manual Safety assessments: The Investigator is responsible for the detection, reporting, and documentation of events meeting the definition of an Adverse Event (AE) and/or Serious Injuries as provided in this clinical investigation plan from the time that informed consent has been provided and during the study period Criteria for evaluations: This is an observational, pilot study and there are currently no plans for a formal statistical analysis. Information gained from this study may used to design subsequent studies in patients with chronic obstructive airways disease. Information collected will be summarized in a clinical study report but will not be subject to formal hypothesis testing

Primary Outcome

Spirometry values were collected according to American Thoracic Society (ATS) guidelines (ATS, 2005). In the event that spirometry preceded forced exhaled nitric oxide (FeNO) measurements, a wait of not less than 20 minutes was imposed to separate the two procedures. Parameters measured were Forced Expiratory Volume in One Second (FEV1), Forced Vital Capacity (FVC), Forced Expiratory Flow 25-75 (FEF15%-75%), Forced Expiratory Flow 50 (FEF50), and Peak Expiratory Flow (PEF). Spirometry measures t

Interventions

  • DEVICE NIOX MINO® Instrument (09-1100)

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2012-06
Est. Completion 2012-10
Aerocrine AB

5 total trials

What the finished NCT01634620 record still lists

NCT01634620 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 1 intervention - of which NIOX MINO® Instrument (09-1100) is the first listed.

NCT01634620 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01634620 about?

NCT01634620 is a clinical study titled "Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease". Objective: To characterize FeNO levels that may be indicative of eosinophilic airway inflammation in patients with chronic obstructive airways disease Number of participants: Approximately 200 subjects will be enrolled Reference product: NIOX MINO® Instrument (09-1100) Performance assessments: Fr...

What is the current status of trial NCT01634620?

This trial is currently completed. The enrollment target is 200 participants. The study started on 2012-06. Estimated completion is 2012-10.

What interventions are being tested in trial NCT01634620?

The interventions under investigation include: NIOX MINO® Instrument (09-1100) (DEVICE).

Who is sponsoring clinical trial NCT01634620?

This trial is sponsored by Aerocrine AB, which has 5 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01634620, the US trial registry maintained by the National Library of Medicine. NCT01634620 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.